# Difference Between Hodgkin Lymphoma and Non Hodgkin Lymphoma

Author: Nex Virox Team (Editorial Team)  
Reviewed by: Varshal Nirbhavane  
Published: 2026-08-27  
Last updated: 2026-08-27  
Canonical: https://nexvirox.com/difference-between/difference-between-hodgkin-and-non-hodgkin-lymphoma/

**Quick answer:** The main difference between Hodgkin Lymphoma and Non Hodgkin Lymphoma is that Hodgkin Lymphoma contains distinctive Reed-Sternberg cells, while Non Hodgkin Lymphoma does not. Hodgkin Lymphoma is a cancer of the lymphatic system that typically spreads predictably between lymph node groups, while Non Hodgkin Lymphoma is a diverse group of blood cancers that often spreads unpredictably throughout the body.

<h2>Difference Between Hodgkin Lymphoma and Non Hodgkin Lymphoma: Comparison Table</h2>
<table>
<thead>
<tr><th>Aspect</th><th>Hodgkin Lymphoma</th><th>Non Hodgkin Lymphoma</th></tr>
</thead>
<tbody>
<tr><td><strong>Definition</strong></td><td>A blood cancer marked by the presence of Reed-Sternberg cells in lymph nodes.</td><td>A diverse group of blood cancers that lack Reed-Sternberg cells in lymphatic tissue.</td></tr>
<tr><td><strong>Origin Cell</strong></td><td>Typically arises from B lymphocytes, specifically germinal center B cells.</td><td>Can originate from B cells, T cells, or natural killer cells.</td></tr>
<tr><td><strong>Reed-Sternberg Cells</strong></td><td>Large abnormal B cells that are the hallmark diagnostic feature.</td><td>Absent; their absence helps pathologists distinguish this cancer from Hodgkin lymphoma.</td></tr>
<tr><td><strong>Disease Pattern</strong></td><td>Tends to spread predictably from one lymph node group to adjacent groups.</td><td>Spreads unpredictably and often involves multiple non-contiguous lymph node sites.</td></tr>
<tr><td><strong>Nodal Involvement</strong></td><td>Usually starts in a single node, often in the neck, chest, or armpit.</td><td>Frequently involves multiple nodes across different body regions at diagnosis.</td></tr>
<tr><td><strong>Extranodal Spread</strong></td><td>Less common; extranodal involvement occurs in advanced stages.</td><td>More common; often affects bone marrow, liver, gastrointestinal tract, and skin.</td></tr>
<tr><td><strong>Age Distribution</strong></td><td>Shows a bimodal pattern with peaks in young adults and those over 55.</td><td>Incidence rises steadily with age, with median diagnosis around 67 years.</td></tr>
<tr><td><strong>Prevalence</strong></td><td>Accounts for roughly 10 percent of all lymphoma diagnoses.</td><td>Accounts for approximately 90 percent of all lymphoma cases globally.</td></tr>
<tr><td><strong>Incidence Rate</strong></td><td>About 3 cases per 100,000 people each year in developed countries.</td><td>About 19 cases per 100,000 people annually in similar populations.</td></tr>
<tr><td><strong>Subtypes</strong></td><td>Divided into nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.</td><td>Includes over 60 distinct subtypes, such as diffuse large B-cell and follicular.</td></tr>
<tr><td><strong>Common Subtype</strong></td><td>Nodular sclerosis is the most frequent, seen in about 70 percent of cases.</td><td>Diffuse large B-cell lymphoma is the most common, representing roughly 30 percent.</td></tr>
<tr><td><strong>B Symptoms</strong></td><td>Fever, night sweats, and weight loss appear in about 40 percent of patients.</td><td>B symptoms occur less frequently but still signal aggressive disease when present.</td></tr>
<tr><td><strong>Pruritus</strong></td><td>Severe itching is a classic symptom, often occurring after alcohol intake.</td><td>Itching is less characteristic and usually appears only with widespread disease.</td></tr>
<tr><td><strong>Diagnostic Marker</strong></td><td>CD15 and CD30 antigens are typically positive on Reed-Sternberg cells.</td><td>Markers vary by subtype; CD20 is common in B-cell lymphomas.</td></tr>
<tr><td><strong>Biopsy Finding</strong></td><td>Shows scattered Reed-Sternberg cells within a mixed inflammatory background.</td><td>Shows a monomorphic sheet of malignant lymphocytes without Reed-Sternberg cells.</td></tr>
<tr><td><strong>Staging System</strong></td><td>Uses the Ann Arbor staging system with A or B symptom classification.</td><td>Uses the same Ann Arbor system but adds extranodal involvement details.</td></tr>
<tr><td><strong>PET-CT Role</strong></td><td>Essential for staging and for assessing early treatment response.</td><td>Important for staging aggressive subtypes, especially diffuse large B-cell lymphoma.</td></tr>
<tr><td><strong>Treatment Intent</strong></td><td>Curative intent is standard even for advanced-stage disease.</td><td>Curative for aggressive subtypes; indolent types often managed expectantly.</td></tr>
<tr><td><strong>Chemotherapy Regimen</strong></td><td>ABVD regimen uses doxorubicin, bleomycin, vinblastine, and dacarbazine.</td><td>R-CHOP regimen uses rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone.</td></tr>
<tr><td><strong>Radiation Use</strong></td><td>Frequently combined with chemotherapy for early-stage bulky disease.</td><td>Used less often; reserved for localized indolent or select aggressive cases.</td></tr>
<tr><td><strong>Stem Cell Transplant</strong></td><td>Autologous transplant is used for relapsed or refractory disease.</td><td>Autologous transplant is standard for relapsed aggressive subtypes; allogeneic for select cases.</td></tr>
<tr><td><strong>Treatment Response</strong></td><td>Responds rapidly to initial chemotherapy, often within two cycles.</td><td>Response varies widely by subtype, from slow indolent to rapid aggressive.</td></tr>
<tr><td><strong>Five-Year Survival</strong></td><td>Overall survival is approximately 87 percent across all stages.</td><td>Overall survival is approximately 72 percent but varies greatly by subtype.</td></tr>
<tr><td><strong>Curability</strong></td><td>Highly curable; even advanced stages have cure rates above 70 percent.</td><td>Cure rates range from under 30 percent for some T-cell types to over 90 percent.</td></tr>
<tr><td><strong>Relapse Pattern</strong></td><td>Relapses typically occur within the first five years after treatment.</td><td>Indolent subtypes relapse continuously; aggressive types relapse within two years.</td></tr>
<tr><td><strong>Late Effects</strong></td><td>Second cancers and cardiac toxicity from radiation are significant concerns.</td><td>Risk of late effects depends on specific chemotherapy agents used.</td></tr>
<tr><td><strong>Genetic Drivers</strong></td><td>JAK-STAT pathway alterations are frequently identified in tumor cells.</td><td>MYC, BCL2, and BCL6 rearrangements drive many aggressive subtypes.</td></tr>
<tr><td><strong>Typical Patient</strong></td><td>Often a young adult aged 20 to 34 presenting with neck lymphadenopathy.</td><td>Usually an older adult over 60 with abdominal or widespread nodal disease.</td></tr>
<tr><td><strong>Watchful Waiting</strong></td><td>Rarely used because most cases are curable with immediate therapy.</td><td>Standard approach for asymptomatic indolent subtypes like follicular lymphoma.</td></tr>
<tr><td><strong>Best-Fit Scenario</strong></td><td>Young patient with localized neck node and classic B symptoms.</td><td>Older patient with widespread nodal and extranodal involvement at diagnosis.</td></tr>
</tbody>
</table>

<h2>What Is Hodgkin Lymphoma?</h2>
<p>Hodgkin Lymphoma is a cancer of the lymphatic system, specifically marked by the presence of Reed-Sternberg cells. It typically begins in lymph nodes, often in the neck or chest, and spreads in a predictable, orderly manner. This disease exists because abnormal B-lymphocytes multiply uncontrollably, weakening the body's immune defenses.</p>
<h3>Definition of Hodgkin Lymphoma</h3>
<p>Hodgkin Lymphoma is a malignant neoplasm of B-cell origin, distinguished histologically by large, multinucleated Reed-Sternberg cells within an inflammatory background. It arises in lymph nodes and can involve extranodal sites, but its contiguous spread pattern and high cure rate separate it from other lymphomas. This precise diagnosis requires biopsy confirmation.</p>
<h3>Key Characteristics of Hodgkin Lymphoma</h3>
<table>
<thead>
<tr><th>Characteristic</th><th>What It Means in Practice</th></tr>
</thead>
<tbody>
<tr><td>Reed-Sternberg cells</td><td>Large abnormal cells found on biopsy; their presence is the definitive diagnostic hallmark.</td></tr>
<tr><td>Contiguous spread</td><td>Cancer moves from one lymph node group to the next, making staging more predictable.</td></tr>
<tr><td>Young adult peak</td><td>Most common in two age groups: 15-35 years and after age 55.</td></tr>
<tr><td>B symptoms</td><td>Unexplained fever, night sweats, and weight loss often appear early in the disease course.</td></tr>
<tr><td>Pain after alcohol</td><td>Rare but specific symptom where affected nodes ache shortly after drinking alcohol.</td></tr>
<tr><td>High cure rate</td><td>Over 85% of patients are cured, even with advanced-stage disease, using modern therapy.</td></tr>
<tr><td>Nodal origin</td><td>Typically starts in cervical, supraclavicular, or mediastinal lymph nodes, not in organs.</td></tr>
<tr><td>Nodular sclerosis type</td><td>Most common subtype, often affecting young women with bulky mediastinal masses.</td></tr>
<tr><td>Chemosensitivity</td><td>Responds very well to chemotherapy and radiation, allowing shorter treatment courses.</td></tr>
<tr><td>HIV association</td><td>Risk is higher in immunocompromised individuals, but standard treatment still works effectively.</td></tr>
</tbody>
</table>
<h3>Common Examples of Hodgkin Lymphoma</h3>
<ul>
<li><strong>Nodular sclerosis Hodgkin lymphoma</strong> – the most frequent subtype, commonly presenting with a large chest mass in young adults.</li>
<li><strong>Mixed cellularity Hodgkin lymphoma</strong> – often linked to Epstein-Barr virus, appearing in older adults and abdominal nodes.</li>
<li><strong>Lymphocyte-rich classic Hodgkin lymphoma</strong> – a rare form with few Reed-Sternberg cells and many normal lymphocytes present.</li>
<li><strong>Lymphocyte-depleted Hodgkin lymphoma</strong> – the rarest subtype, frequently seen in older or HIV-positive patients with aggressive disease.</li>
<li><strong>Classic Hodgkin lymphoma, not otherwise specified</strong> – a diagnostic category used when the subtype cannot be precisely classified.</li>
<li><strong>Nodular lymphocyte-predominant Hodgkin lymphoma</strong> – a distinct entity with popcorn-shaped cells, behaving more indolently than classic forms.</li>
<li><strong>Primary mediastinal large B-cell lymphoma</strong> – often confused with Hodgkin due to similar chest symptoms, but biologically different.</li>
<li><strong>Epstein-Barr virus-positive Hodgkin lymphoma</strong> – a viral-driven variant seen more often in developing countries and in children.</li>
<li><strong>Early-stage favorable Hodgkin lymphoma</strong> – limited to one or two node regions, typically treated with short chemotherapy plus radiation.</li>
<li><strong>Advanced-stage Hodgkin lymphoma</strong> – involving multiple node groups or organs, still curable with intensive combination regimens.</li>
</ul>
<h3>Advantages and Limitations of Hodgkin Lymphoma</h3>
<table>
<thead>
<tr><th>Advantages</th><th>Limitations</th></tr>
</thead>
<tbody>
<tr><td>Extremely high cure rate, exceeding 85% even in advanced stages, offers strong long-term survival odds.</td><td>Late effects of treatment, including secondary cancers and heart damage, can appear decades after cure.</td></tr>
<tr><td>Predictable spread pattern allows for less extensive radiation fields and more targeted therapy planning.</td><td>Chemotherapy regimens like ABVD carry significant short-term toxicity, including nausea, hair loss, and fertility impairment.</td></tr>
<tr><td>Reed-Sternberg cells make diagnosis unambiguous, reducing the risk of misdiagnosis compared to other lymphomas.</td><td>Biopsy is invasive and sometimes requires surgical excision of a deep node, not just a needle sample.</td></tr>
<tr><td>Many patients respond completely to first-line therapy, avoiding the need for transplant or salvage treatment.</td><td>Relapsed disease is harder to cure, requiring high-dose chemotherapy and stem cell transplant with serious risks.</td></tr>
<tr><td>Modern PET-guided therapy reduces radiation exposure by tailoring treatment to early response, sparing healthy tissue.</td><td>Radiation to the chest increases the risk of breast cancer and coronary artery disease in young female survivors.</td></tr>
<tr><td>B symptoms are a reliable early warning sign, prompting quicker diagnosis and treatment initiation.</td><td>Persistent fatigue and cognitive issues, known as chemo brain, can last for years after therapy ends.</td></tr>
<tr><td>Well-defined staging systems (Ann Arbor) allow precise prognosis and risk-adapted treatment decisions.</td><td>Patients with bulky mediastinal masses may need additional radiation, raising long-term organ toxicity concerns.</td></tr>
<tr><td>Immunotherapy and targeted drugs offer effective options for relapsed cases without the toxicity of traditional chemo.</td><td>Treatment costs are high, and access to novel agents remains limited in many healthcare systems worldwide.</td></tr>
<tr><td>HIV-associated Hodgkin lymphoma responds well to standard therapy when antiretroviral treatment is maintained.</td><td>Immunocompromised patients face higher infection risks during chemotherapy, complicating their management.</td></tr>
<tr><td>Clinical trials continuously improve outcomes, with new combinations reducing both relapse rates and side effects.</td><td>Even cured patients require lifelong surveillance for late complications, adding emotional and financial burdens.</td></tr>
</tbody>
</table>

<h2>What Is Non Hodgkin Lymphoma?</h2>
<p>Non Hodgkin Lymphoma is a cancer that starts in white blood cells called lymphocytes. It causes abnormal cells to multiply in lymph nodes and lymphatic tissue. This disease develops when lymphocytes grow out of control instead of fighting infection normally.</p>
<h3>Definition of Non Hodgkin Lymphoma</h3>
<p>Non Hodgkin Lymphoma is a heterogeneous group of malignant neoplasms arising from B lymphocytes, T lymphocytes, or natural killer cells. These cancers originate in the lymphatic system and typically present as painless lymph node enlargement. The classification excludes Hodgkin lymphoma based on the absence of Reed-Sternberg cells.</p>
<h3>Key Characteristics of Non Hodgkin Lymphoma</h3>
<table>
<thead>
<tr><th>Characteristic</th><th>What It Means in Practice</th></tr>
</thead>
<tbody>
<tr><td>Rapid onset</td><td>Lymph nodes can swell noticeably within weeks rather than over many months.</td></tr>
<tr><td>Widespread disease</td><td>Cancer often appears in multiple lymph node groups or organs at diagnosis.</td></tr>
<tr><td>Extranodal involvement</td><td>Tumours frequently start in the stomach, skin, brain, or bone marrow.</td></tr>
<tr><td>Variable aggressiveness</td><td>Some subtypes grow slowly for years while others spread within days.</td></tr>
<tr><td>B symptoms</td><td>Night sweats, persistent fever, and unexplained weight loss occur commonly.</td></tr>
<tr><td>Older age profile</td><td>Most patients receive a diagnosis after age 60, though all ages can be affected.</td></tr>
<tr><td>B-cell origin</td><td>About 85 percent of cases derive from B lymphocytes rather than T cells.</td></tr>
<tr><td>Immunosuppression link</td><td>HIV infection, organ transplantation, and autoimmune diseases raise the risk.</td></tr>
<tr><td>No Reed-Sternberg cells</td><td>Biopsy shows malignant cells that differ from the giant cells of Hodgkin disease.</td></tr>
<tr><td>Chemotherapy response</td><td>Most aggressive subtypes respond well to combination drug regimens initially.</td></tr>
</tbody>
</table>
<h3>Common Examples of Non Hodgkin Lymphoma</h3>
<ul>
<li><strong>Diffuse Large B-Cell Lymphoma</strong> – the most frequent aggressive subtype, making up roughly one-third of all cases.</li>
<li><strong>Follicular Lymphoma</strong> – a slow-growing B-cell cancer that often responds well but tends to relapse.</li>
<li><strong>Chronic Lymphocytic Leukemia</strong> – a low-grade lymphoma that primarily affects blood and bone marrow.</li>
<li><strong>Mantle Cell Lymphoma</strong> – an aggressive B-cell disease with a characteristic cyclin D1 genetic marker.</li>
<li><strong>Burkitt Lymphoma</strong> – a highly aggressive tumour with very rapid doubling time, often linked to Epstein-Barr virus.</li>
<li><strong>Marginal Zone Lymphoma</strong> – an indolent subtype frequently associated with chronic infection or autoimmune inflammation.</li>
<li><strong>Peripheral T-Cell Lymphoma</strong> – a diverse group of aggressive cancers arising from mature T lymphocytes.</li>
<li><strong>Mycosis Fungoides</strong> – a cutaneous T-cell lymphoma that first appears as skin patches or plaques.</li>
<li><strong>Lymphoplasmacytic Lymphoma</strong> – a rare B-cell neoplasm that secretes IgM and causes hyperviscosity syndrome.</li>
<li><strong>Anaplastic Large Cell Lymphoma</strong> – a T-cell cancer that expresses CD30 and can appear in skin or lymph nodes.</li>
</ul>
<h3>Advantages and Limitations of Non Hodgkin Lymphoma</h3>
<table>
<thead>
<tr><th>Advantages</th><th>Limitations</th></tr>
</thead>
<tbody>
<tr><td>Many aggressive subtypes respond dramatically to first-line combination chemotherapy.</td><td>Relapse is common in indolent forms, so cure remains elusive for many patients.</td></tr>
<tr><td>Targeted therapies like rituximab have substantially improved survival for B-cell disease.</td><td>Treatment resistance develops in a significant fraction of patients after initial response.</td></tr>
<tr><td>Modern imaging allows precise staging and accurate monitoring of treatment response.</td><td>Chemotherapy carries serious side effects including infection risk, neuropathy, and organ damage.</td></tr>
<tr><td>Slow-growing subtypes may require no immediate therapy, sparing patients unnecessary toxicity.</td><td>Watchful waiting creates anxiety because patients live with untreated cancer indefinitely.</td></tr>
<tr><td>Stem cell transplantation offers curative potential for selected relapsed patients.</td><td>Transplant procedures carry a mortality risk and require prolonged hospitalisation.</td></tr>
<tr><td>CAR-T cell therapy achieves durable remissions in some refractory aggressive cases.</td><td>CAR-T therapy is extremely expensive and can trigger severe cytokine release syndrome.</td></tr>
<tr><td>Biopsy-based subtyping guides highly specific treatment protocols for each variant.</td><td>Diagnosis requires invasive tissue sampling, which may be difficult for deep tumours.</td></tr>
<tr><td>Immunotherapy agents harness the immune system to attack lymphoma cells effectively.</td><td>Immune-related side effects such as colitis and pneumonitis can become life-threatening.</td></tr>
<tr><td>Radiation therapy effectively controls localised disease in selected low-grade cases.</td><td>Radiation increases the long-term risk of secondary solid tumours and heart disease.</td></tr>
<tr><td>Clinical trials offer access to novel agents before they reach general availability.</td><td>Trial participation may require travel, extra tests, and uncertain benefit for the patient.</td></tr>
</tbody>
</table>

<h2>Similarities Between Hodgkin Lymphoma and Non Hodgkin Lymphoma</h2>
<table>
<thead>
<tr><th>Shared Aspect</th><th>How Hodgkin Lymphoma and Non Hodgkin Lymphoma Are Alike</th></tr>
</thead>
<tbody>
<tr><td><strong>Cancer Origin</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma begin in lymphocytes, a type of white blood cell in the lymphatic system.</td></tr>
<tr><td><strong>Lymphatic System</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both develop within lymph nodes, spleen, bone marrow, and other lymphatic tissues.</td></tr>
<tr><td><strong>Swollen Nodes</strong></td><td>Painless swollen lymph nodes in the neck, armpits, or groin are the most common first sign for Hodgkin lymphoma and non Hodgkin lymphoma.</td></tr>
<tr><td><strong>B Symptoms</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both cause fever, drenching night sweats, and unexplained weight loss when advanced.</td></tr>
<tr><td><strong>Immune Impact</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both weaken immune function, increasing susceptibility to serious infections during treatment.</td></tr>
<tr><td><strong>Diagnostic Biopsy</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma require an excisional lymph node biopsy for accurate diagnosis and subtyping.</td></tr>
<tr><td><strong>Imaging Staging</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both use PET-CT scans to determine disease stage and guide treatment planning.</td></tr>
<tr><td><strong>Staging System</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma are staged using the Ann Arbor system, ranging from stage I to stage IV.</td></tr>
<tr><td><strong>Treatment Backbone</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both rely on chemotherapy as the primary initial treatment in most cases.</td></tr>
<tr><td><strong>Radiation Role</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma may use targeted radiation therapy to treat localized or bulky disease.</td></tr>
<tr><td><strong>Immunotherapy Use</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both respond to monoclonal antibodies like rituximab or checkpoint inhibitors in certain subtypes.</td></tr>
<tr><td><strong>Targeted Drugs</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma can be treated with small-molecule inhibitors that target specific cancer-driving mutations.</td></tr>
<tr><td><strong>Stem Cell Transplant</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both use autologous stem cell transplantation for relapsed or refractory disease.</td></tr>
<tr><td><strong>Relapse Risk</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma carry a risk of disease recurrence after initial remission, requiring ongoing surveillance.</td></tr>
<tr><td><strong>Remission Goal</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both aim for complete remission, meaning no detectable cancer after treatment.</td></tr>
<tr><td><strong>Response Monitoring</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma are monitored with repeated PET-CT scans to assess treatment response.</td></tr>
<tr><td><strong>Blood Testing</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both require regular complete blood counts and lactate dehydrogenase levels during care.</td></tr>
<tr><td><strong>Bone Marrow</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma can infiltrate bone marrow, affecting blood cell production and staging.</td></tr>
<tr><td><strong>Age Factors</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both show incidence peaks in specific age groups, though the exact ages differ.</td></tr>
<tr><td><strong>Gender Bias</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma occur slightly more often in males than in females across most populations.</td></tr>
<tr><td><strong>Genetic Mutations</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both arise from acquired genetic changes in lymphocytes that drive uncontrolled growth.</td></tr>
<tr><td><strong>Epstein-Barr Link</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma have documented associations with Epstein-Barr virus infection in some cases.</td></tr>
<tr><td><strong>Immunodeficiency Risk</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both occur more frequently in people with HIV or other immunosuppressed conditions.</td></tr>
<tr><td><strong>Chemo Side Effects</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma treatments both cause nausea, fatigue, hair loss, and lowered blood counts.</td></tr>
<tr><td><strong>Long-Term Toxicity</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma survivors face increased risks of secondary cancers and heart disease.</td></tr>
<tr><td><strong>Fertility Risks</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma treatments both can impair fertility, prompting egg or sperm banking discussions.</td></tr>
<tr><td><strong>Survival Tracking</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma outcomes are measured using five-year overall survival and progression-free survival rates.</td></tr>
<tr><td><strong>Multidisciplinary Care</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both require coordinated care from hematologists, oncologists, radiologists, and pathologists.</td></tr>
<tr><td><strong>Clinical Trials</strong></td><td>Both Hodgkin lymphoma and non Hodgkin lymphoma patients may access novel therapies through enrollment in clinical trials.</td></tr>
<tr><td><strong>Supportive Care</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma both benefit from infection prophylaxis, growth factors, and transfusion support during treatment.</td></tr>
</tbody>
</table>

<h2>Hodgkin Lymphoma or Non Hodgkin Lymphoma: Which Should You Choose?</h2>
<p>You do not choose between these two cancers; a biopsy determines which one you have. The single decisive variable is the presence of <strong>Reed-Sternberg cells</strong> under a microscope. Hodgkin lymphoma always shows these large abnormal cells; non Hodgkin lymphoma never does. This one lab finding sets your entire treatment path.</p>
<h3>When to Use Hodgkin Lymphoma</h3>
<p>Choose Hodgkin Lymphoma when a biopsy confirms <strong>Reed-Sternberg cells</strong> are present. This diagnosis typically affects younger adults aged 15 to 35 and older adults over 55. Hodgkin lymphoma usually starts in a single lymph node group, spreads predictably, and responds well to ABVD chemotherapy. The five-year survival rate exceeds 87 percent.</p>
<h3>When to Use Non Hodgkin Lymphoma</h3>
<p>Choose Non Hodgkin Lymphoma when biopsy results show <strong>no Reed-Sternberg cells</strong>. This diagnosis covers over 60 distinct subtypes, including diffuse large B-cell lymphoma and follicular lymphoma. Non Hodgkin lymphoma often appears in multiple lymph node areas at once, spreads unpredictably, and affects older adults, with a median diagnosis age of 67. Treatment varies by subtype.</p>

<h2>Common Misconceptions About Hodgkin Lymphoma and Non Hodgkin Lymphoma</h2><table><thead><tr><th>Common Myth</th><th>The Reality</th></tr></thead><tbody><tr><td><strong>Hodgkin lymphoma is always more dangerous than non Hodgkin lymphoma.</strong></td><td>Non Hodgkin lymphoma is usually more aggressive and harder to cure than Hodgkin lymphoma, which responds well to modern therapy.</td></tr><tr><td><strong>Hodgkin lymphoma and non Hodgkin lymphoma are the exact same disease.</strong></td><td>Hodgkin lymphoma contains Reed-Sternberg cells, while non Hodgkin lymphoma lacks them, making the two distinct cancer types.</td></tr><tr><td><strong>Only older adults develop non Hodgkin lymphoma, never young people.</strong></td><td>Non Hodgkin lymphoma can occur at any age, although its risk does rise steadily as a person gets older.</td></tr><tr><td><strong>Hodgkin lymphoma is always fatal if you receive a diagnosis.</strong></td><td>Hodgkin lymphoma has a five-year survival rate near 90 percent, making it one of the most curable cancers.</td></tr><tr><td><strong>Swollen lymph nodes always mean you have lymphoma.</strong></td><td>Most swollen lymph nodes come from infections, and only a biopsy can confirm Hodgkin or non Hodgkin lymphoma.</td></tr><tr><td><strong>Non Hodgkin lymphoma is a single, simple disease with one treatment.</strong></td><td>Non Hodgkin lymphoma includes over 60 subtypes, each with different behaviors, treatments, and prognosis.</td></tr><tr><td><strong>Hodgkin lymphoma spreads faster than non Hodgkin lymphoma does.</strong></td><td>Hodgkin lymphoma typically spreads in a predictable, orderly way, while non Hodgkin lymphoma often spreads unpredictably and faster.</td></tr><tr><td><strong>Lymphoma is the same thing as leukemia in every respect.</strong></td><td>Lymphoma starts in lymph nodes, while leukemia starts in bone marrow, though both are blood cancers.</td></tr><tr><td><strong>You can catch lymphoma from someone who has it.</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma are not contagious, so you cannot catch either from another person.</td></tr><tr><td><strong>Painful lymph nodes are a sure sign of lymphoma.</strong></td><td>Lymphoma nodes are usually painless, while painful nodes more often indicate an infection rather than cancer.</td></tr><tr><td><strong>Non Hodgkin lymphoma only affects men, not women.</strong></td><td>Non Hodgkin lymphoma affects both sexes, though the overall incidence is slightly higher in males.</td></tr><tr><td><strong>Hodgkin lymphoma always causes visible symptoms early on.</strong></td><td>Hodgkin lymphoma often causes no symptoms at first, and many cases are found during routine imaging.</td></tr><tr><td><strong>Chemotherapy is the only treatment option for either lymphoma.</strong></td><td>Hodgkin and non Hodgkin lymphoma may be treated with radiation, targeted therapy, immunotherapy, or stem cell transplants.</td></tr><tr><td><strong>Night sweats alone prove you have non Hodgkin lymphoma.</strong></td><td>Night sweats have many causes, and non Hodgkin lymphoma requires biopsy confirmation alongside other symptoms.</td></tr><tr><td><strong>Hodgkin lymphoma always comes back after successful treatment.</strong></td><td>Most Hodgkin lymphoma patients stay in remission permanently, and relapse occurs only in a minority of cases.</td></tr><tr><td><strong>Non Hodgkin lymphoma is always caused by smoking or drinking.</strong></td><td>Most non Hodgkin lymphoma cases have no clear cause, with risk factors including immune disorders and certain infections.</td></tr><tr><td><strong>Children never get Hodgkin lymphoma at all.</strong></td><td>Hodgkin lymphoma does occur in children and teenagers, though it is most common in young adults.</td></tr><tr><td><strong>If one lymph node is swollen, the cancer has spread everywhere.</strong></td><td>Hodgkin lymphoma spreads stepwise through lymph node groups, and staging determines the true extent of disease.</td></tr><tr><td><strong>Non Hodgkin lymphoma always produces a visible lump on the skin.</strong></td><td>Non Hodgkin lymphoma often causes no external lump, with symptoms like fatigue, fever, or weight loss appearing first.</td></tr><tr><td><strong>Hodgkin lymphoma and non Hodgkin lymphoma need identical treatment plans.</strong></td><td>Hodgkin lymphoma and non Hodgkin lymphoma require different regimens, because their cell types and growth rates differ.</td></tr><tr><td><strong>Lymphoma is caused by stress or negative thinking.</strong></td><td>Stress does not cause Hodgkin or non Hodgkin lymphoma, which arise from genetic mutations in white blood cells.</td></tr><tr><td><strong>Non Hodgkin lymphoma is always slow-growing and harmless.</strong></td><td>Non Hodgkin lymphoma includes aggressive fast-growing subtypes that require immediate treatment for the best outcome.</td></tr><tr><td><strong>Hodgkin lymphoma is more common than non Hodgkin lymphoma.</strong></td><td>Non Hodgkin lymphoma is far more common, accounting for about 90 percent of all lymphoma diagnoses.</td></tr><tr><td><strong>A blood test alone can diagnose either type of lymphoma.</strong></td><td>Blood tests cannot confirm Hodgkin or non Hodgkin lymphoma; a lymph node biopsy is the only definitive diagnosis.</td></tr><tr><td><strong>Non Hodgkin lymphoma never affects the lymph nodes in the chest.</strong></td><td>Non Hodgkin lymphoma frequently involves chest lymph nodes, especially in certain aggressive subtypes like large B-cell lymphoma.</td></tr><tr><td><strong>Hodgkin lymphoma survival rates are identical for every patient.</strong></td><td>Hodgkin lymphoma survival depends on stage, age, and subtype, with early-stage patients having the best outcomes.</td></tr><tr><td><strong>All lymphomas are hereditary and run in families.</strong></td><td>Most Hodgkin and non Hodgkin lymphoma cases are sporadic, with only a small minority showing any family link.</td></tr><tr><td><strong>Non Hodgkin lymphoma always causes itching all over the body.</strong></td><td>Itching occurs in some non Hodgkin lymphoma patients, but many experience no itching whatsoever during their illness.</td></tr><tr><td><strong>Hodgkin lymphoma patients cannot live normal lives after treatment.</strong></td><td>Most Hodgkin lymphoma survivors return to work, exercise, and full daily routines after completing their therapy.</td></tr><tr><td><strong>Non Hodgkin lymphoma is incurable in every single case.</strong></td><td>Many non Hodgkin lymphoma subtypes are curable, especially aggressive ones like diffuse large B-cell lymphoma treated promptly.</td></tr></tbody></table>

<h2>Conclusion</h2><p>Difference Between Hodgkin Lymphoma and Non Hodgkin Lymphoma comes down to the presence of Reed-Sternberg cells and distinct disease behavior. Hodgkin lymphoma typically spreads predictably between lymph node groups. Non Hodgkin lymphoma often involves multiple nodes unpredictably. Choose Hodgkin for younger patients with localized disease. Choose Non Hodgkin for widespread, aggressive presentations requiring systemic therapy.</p>

## FAQ

### What is the main difference between Hodgkin lymphoma and non Hodgkin lymphoma?
The main difference is the presence of Reed-Sternberg cells, which are large abnormal cells found only in Hodgkin lymphoma, while non Hodgkin lymphoma lacks these cells.

### Which type of lymphoma has a better prognosis, Hodgkin or non Hodgkin?
Hodgkin lymphoma generally has a better prognosis, because it is often diagnosed at an earlier stage and responds very well to standard chemotherapy and radiation treatments.

### Is the treatment cost for Hodgkin lymphoma higher than for non Hodgkin lymphoma?
Treatment cost varies widely by stage and regimen, but non Hodgkin lymphoma often costs more overall because it includes many subtypes that require prolonged or targeted therapies.

### Are the risk factors for Hodgkin lymphoma the same as those for non Hodgkin lymphoma?
No, risk factors differ, as Epstein-Barr virus infection and a family history are stronger risk factors for Hodgkin lymphoma, while autoimmune diseases and certain infections raise non Hodgkin lymphoma risk more.

### Can a biopsy always distinguish between Hodgkin lymphoma and non Hodgkin lymphoma?
Yes, an excisional lymph node biopsy can reliably distinguish them, because pathologists look specifically for Reed-Sternberg cells that confirm Hodgkin lymphoma and their absence indicates non Hodgkin lymphoma.

### What is a common beginner mistake when comparing these two lymphomas?
A common beginner mistake is assuming non Hodgkin lymphoma is one single disease, when it is actually a diverse group of over 60 related but distinct blood cancers.

### Are Hodgkin lymphoma and non Hodgkin lymphoma interchangeable terms for the same cancer?
No, they are not interchangeable, because they are separate diseases with different cell origins, distinct microscopic features, varied growth patterns, and different standard treatment approaches.

### In a real-world case, how does treatment planning differ between the two lymphoma types?
In a real-world case, Hodgkin lymphoma typically uses ABVD chemotherapy with involved-site radiation, whereas non Hodgkin lymphoma treatment depends heavily on the specific subtype and often includes R-CHOP or immunotherapy.

### Can a patient switch from a non Hodgkin lymphoma treatment plan to a Hodgkin lymphoma plan?
No, a patient cannot switch plans, because the chemotherapy regimens are designed for the specific cancer type, and using the wrong protocol would be ineffective and potentially harmful.

### Which lymphoma spreads more predictably through the body, Hodgkin or non Hodgkin?
Hodgkin lymphoma spreads more predictably, because it typically moves from one lymph node group to an adjacent group, whereas non Hodgkin lymphoma often spreads unpredictably to distant sites.